INTRODUCTION
============

The increase in the number of individuals with cancer and their improved prognosis has led to a growing demand for intensive care unit (ICU) management \[[@b1-acc-2018-00143]\]. Even with these changes, some physicians consider ICU management in cancer patients to be a futile effort, and metastatic cancer is a common reason for refusal of ICU admission in practice \[[@b2-acc-2018-00143]\]. Considering the disappointing survival rates of critically ill cancer patients in studies published in the 1980s and 1990s, triaging physicians' refusal ICU admission to cancer patients seems reasonable \[[@b3-acc-2018-00143],[@b4-acc-2018-00143]\].

However, recent investigations have demonstrated that advances in ICU management have led to an improvement of clinical outcomes in patients with and without cancer admitted to the ICU and suggested that critically ill cancer patients should not be excluded from the ICU only because they have cancer \[[@b5-acc-2018-00143],[@b6-acc-2018-00143]\]. Domestic epidemiological data are needed to guide our practice in managing patients with cancer because there are geographic variations in the diagnosis of and type of cancer, but domestic data on clinical characteristics and outcomes in cancer patients are still limited \[[@b7-acc-2018-00143]\]. Therefore, the present study was conducted to investigate the characteristics and clinical outcomes and predictors of mortality in critically ill cancer patients admitted to the ICU in Korea.

MATERIALS AND METHODS
=====================

Study Design and Population
---------------------------

This study used data from the Validation of Simplified Acute Physiology Score 3 (SAPS3) in Korean ICU (VSKI) study. The VSKI study, which is a nationwide, multicenter, and prospective study, was conducted by the Korean Study Group on Respiratory Failure between July 1, 2010 and January 31, 2011 to evaluate the prognostic performance of the SAPS3 in a large prospective cohort in Korea \[[@b8-acc-2018-00143]\]. It included patients from 22 ICUs (14 medical, six surgical, and two multidisciplinary) in 15 tertiary or university-affiliated hospitals. Only the data from the index ICU admission were included.

A total of 5,063 patients were admitted to participating ICUs during the study period. Patients who were older than 18 years of age and diagnosed with solid or hematologic malignancies prior to admission to the ICU were eligible for inclusion in the present study. Among them, we excluded patients if they were electively admitted for postoperative care, transferred from other participating ICUs, or if they had no data available regarding hospital mortality ([Figure 1](#f1-acc-2018-00143){ref-type="fig"}). Patients were followed up until the time of death or hospital discharge. This study was approved by the relevant Institutional Review Board(s) of each participating hospital, and the requirement for informed consent was waived because of the noninterventional nature of the study.

Data Collection and Clinical Outcomes
-------------------------------------

Patient data were collected using a web-based database. The definitions of variables used in the original SAPS3 model were used for this study \[[@b9-acc-2018-00143]\]. We used the most abnormal set of data from the one hour prior to or after ICU admission to calculate SAPS3. The following data were sourced from the medical charts of the participants: demographic data; location prior to ICU admission; reason(s) for ICU admission; infection and surgical status at the time of ICU admission; laboratory data and physiologic measurements, which were collected within 1 hour before and 24 hours after ICU admission; and treatment(s) received during ICU stay. The severity of illness was assessed by the SAPS3 and Sequential Organ Failure Assessment (SOFA) score. The primary outcome in this study was hospital mortality. Secondary outcomes were ICU mortality, length of hospital stay, and length of ICU stay.

Definition
----------

Cancer was categorized as solid or hematologic malignancy. Solid tumors were defined as cancer with proven distant (not regional lymph node) metastasis by surgery, computed tomography scan, or any other appropriate method. Hematologic malignancies were defined as tumors of the hematopoietic and lymphoid tissue including lymphoma, acute leukemia, and multiple myeloma. Infection was defined as the presence of a pathogenic microorganism in a sterile site and/or clinically suspected infection, plus the administration of antibiotics. Severe sepsis and septic shock were defined as sepsis associated with acute organ dysfunction and sepsis with acute circulatory failure characterized by persistent arterial hypotension (i.e., systolic arterial pressure \<90 mmHg, mean arterial pressure \<60 mmHg, or a reduction in systolic blood pressure \>40 mmHg from baseline) despite adequate volume resuscitation, respectively \[[@b10-acc-2018-00143]\]. Acute lung injury and acute respiratory distress syndrome were defined as arterial oxygen pressure to inspiratory oxygen fraction (PaO~2~/FiO~2~) ratio \<300 and \<200, respectively, with the following criteria: acute onset, bilateral infiltrates on chest radiography, and pulmonary artery wedge pressure \<18 mmHg or clinical evidence of left atrial hypertension. An unplanned ICU admission was defined as an admission planned less than 12 hours in advance or any unscheduled admission to the ICU that originated from the emergency department, general ward, operating room, or other location. Performance status was assigned a grade between 0 and 4 according to the Eastern Cooperative Oncology Group performance status classification \[[@b11-acc-2018-00143]\]. We used the definition of variables employed in the original SAPS3 model to define variables in this study \[[@b12-acc-2018-00143]\].

Statistical Analysis
--------------------

Data are presented as median and interquartile range (25th and 75th percentiles) for continuous variables and as numbers (percentages) for categorical variables. Data were compared using the Mann-Whitney U-test for continuous variables and the chi-square or Fisher exact test for categorical variables, respectively, where applicable. Logistic regression analyses were performed to identify risk factors for the prediction of mortality. Variables that appeared to be related in the univariate analysis with a P-value of less than 0.2 were introduced into multivariate regression models using a forward stepwise method. For all analyses, a two-tailed test with a P-value of less than 0.05 was considered to be statistically significant. We used the SPSS version 20.0 (IBM SPSS Corp., Armonk, NY, USA) for statistical analysis.

RESULTS
=======

Baseline Clinical Characteristics
---------------------------------

As shown in [Figure 1](#f1-acc-2018-00143){ref-type="fig"}, a total of 1,762 cancer patients were admitted to the ICUs and 833 of them were deemed eligible for analysis. The baseline characteristics of the 833 eligible patients finally included in the present study are described in [Table 1](#t1-acc-2018-00143){ref-type="table"}. Of these, 554 (66.5%) were male, and the median age was 63 years (range, 53 to 72 years). SOFA score and SAPS3 were 9 (range, 5 to 12) and 69 (range, 60 to 79), respectively. Unplanned admissions composed 74.4% of all ICU admissions. The most common reason for ICU admission was respiratory disease (30.1%), followed by surveillance (27.3%), cardiovascular disease (24.1%), and digestive disease (5.4%). About half of the patients included in this study had acute infection at the time of ICU admission, and most admissions were not related to surgery.

Comparison of Baseline Characteristics According to Type of Malignancy
----------------------------------------------------------------------

Of the 833 patients, 658 (79%) had solid tumors and 175 (21%) had hematologic malignancies. The patients with solid tumors were typically older and more commonly male versus the patients with hematologic malignancies ([Table 2](#t2-acc-2018-00143){ref-type="table"}). Performance status and comorbidities were similar between the two groups, except with regard to hypertension and liver cirrhosis. Patients with hematologic malignancies had higher SOFA and SAPS3 values than did patients with solid tumors. The proportions of patients with a history of chemotherapy (57.1% vs. 32.1%, P\<0.001), steroid therapy (9.1% vs. 2.0%, P\<0.001), and compromised immune status (17.7% vs. 7.3%, P\<0.001) were significantly higher in the hematologic malignancies group, while, conversely, the proportion of patients who had undergone radiotherapy (13.8% vs. 8.0%, P=0.040) was higher in the solid tumor group. Unplanned ICUs admissions occurred more frequently among hematologic malignancy patients than among solid tumor patients. Respiratory (35.4% vs. 28.7%, P=0.095) and cardiovascular (34.9% vs. 21.3%, P\<0.001) problems were common causes of ICU admission in both groups, with the exception of admission for surveillance. More patients with hematologic cancer showed an acute infection status at the time of ICU admission. In addition, rates of severe sepsis/septic shock were significantly higher in patients with hematologic cancer as compared with those with solid cancer (57.1% vs. 32.2%, P\<0.001).

ICU Treatments
--------------

The amount of total fluid administered within 24 hours (4,039 ml vs. 3,339 ml, P\<0.001) was higher and the use of an inotrope/vasopressor (54.8% vs. 44.7%, P=0.017) was more prevalent, respectively, in patients with hematologic malignancies. In addition, hematologic malignancy patients more frequently required mechanical ventilation (46.9% vs. 33.3%, P=0.001) and continuous renal replacement therapy (17.6% vs. 9.5%, P=0.004) than did solid tumor patients.

Clinical Outcomes
-----------------

Overall, 235 patients (28.2%) died in the ICU, while 112 patients (13.4%) died while hospitalized in other wards ([Figure 2](#f2-acc-2018-00143){ref-type="fig"}). Both ICU (41.7% vs. 24.6%, P\<0.001) and hospital (53.1% vs. 38.6%, P=0.002) mortality rates were significantly higher in patients with hematologic malignancies than in patients with solid tumors. Multivariable logistic regression analysis revealed that age, demonstration of performance status 2 through 4, mechanical ventilation usage, and SAPS3 in solid tumor patients ([Table 3](#t3-acc-2018-00143){ref-type="table"}) and mechanical ventilation usage and SAPS3 in hematologic malignancy patients were significant prognostic predictors for hospital mortality ([Table 3](#t3-acc-2018-00143){ref-type="table"}).

In the total patient cohort, ICU length of stay and hospital length of stay were 5 days (range, 3 to 10 days) and 20 days (range, 11 to 39 days), respectively. Although the ICU length of stay (5 days vs. 6 days, P=0.160) was similar between patients with solid tumor and those with hematologic malignancies, the hospital length of stay (28 days vs. 19 days, P=0.001) was noticeably longer in hematologic malignancy patients.

DISCUSSION
==========

In this study, we investigated the epidemiology, characteristics, and clinical outcomes of critically ill cancer patients in Korea. Within our cohort, patients with cancer accounted for 34.8% of the total number of patients admitted to participating ICUs during the study period, and respiratory and cardiovascular diseases were two of the common causes of ICU admission in patients with malignancies. Our percentage of cancer patients admitted was relatively higher than those seen in the results of other previous studies that were conducted involving a mixed population, which ranged from 13.5% to 21.5% of overall ICU admissions \[[@b5-acc-2018-00143],[@b13-acc-2018-00143],[@b14-acc-2018-00143]\]. Although it is difficult to compare our results to those of other investigations directly because our study did not examine the details of cancer, geographic variations in incidence and type of cancer may have an effect on the gap in the proportion of cancer patients admitted to the ICU \[[@b7-acc-2018-00143]\].

Acute respiratory failure was identified as one of the most common medical conditions causing cancer patients to enter the ICU in previous studies as well as in our study \[[@b13-acc-2018-00143],[@b15-acc-2018-00143],[@b16-acc-2018-00143]\]. The incidence of acute respiratory failure in cancer patients ranges from 10% to 50%, and the risk of respiratory failure is higher in patients with hematologic malignancies, especially in patients who received allogeneic stem cell transplantation, as compared with in patients with solid tumor \[[@b6-acc-2018-00143],[@b17-acc-2018-00143],[@b18-acc-2018-00143]\]. The most common cause of acute respiratory failure is pulmonary infection, but treatment-associated pulmonary toxicities, transfusion-related acute lung injury, lung involvement of underlying malignancy, and malignant airway obstruction also can cause a case of acute respiratory failure that requires ICU management \[[@b18-acc-2018-00143]\].

Patients with hematologic malignancies have some clinical characteristics different from those of patients with solid tumor \[[@b13-acc-2018-00143]\]. In our study, the proportion of patients who received chemotherapy and steroid therapy and that of patients with immunosuppression were higher, and observations of acute infection and severe sepsis/septic shock at the time of ICU admission were more frequent in patients with hematologic malignancies than in patients with solid tumor. In addition to a higher baseline SOFA score, the frequencies of vasopressor use, mechanical ventilation, and continuous renal replacement therapy during ICU treatment were all significantly higher in patients with hematologic malignancies. These findings are consistent with those of previous studies that showed that patients with hematologic malignancies are more likely to develop severe sepsis or septic shock in comparison with patients with solid tumor \[[@b13-acc-2018-00143]\]. Neutropenia often occurs in hematologic malignancy patients due to an association with the underlying malignancy itself or chemotherapy; for example, in our study, the white blood cell counts in hematologic malignancy patients were significantly lower than those in solid tumor patients, and it is known that neutropenic patients are more vulnerable to bacterial or fungal infections that have the potential to cause sepsis \[[@b19-acc-2018-00143],[@b20-acc-2018-00143]\].

Also, in regard to prognosis, solid tumor patients and hematologic malignancy patients showed different results. Although variations exist with regard to the type of cancer, patients with solid tumor have a global hospital mortality rate of 25% to 40%, and some studies have demonstrated that mortality in this population is similar to that in ICU patients without cancer \[[@b14-acc-2018-00143],[@b21-acc-2018-00143]\]. On the other hand, the hospital mortality rate of patients with hematologic malignancies is about 40% to 70%, which is generally worse than that in solid tumor patients \[[@b6-acc-2018-00143],[@b22-acc-2018-00143]\]. In particular, the mortality rate of patients with hematologic malignancies who receive hematopoietic stem cell transplantation is concerning, even in recent studies, at 63% to 75% \[[@b23-acc-2018-00143],[@b24-acc-2018-00143]\]. Hospital mortality rates in solid tumor patients and hematologic malignancy patients in our study were 38.6% and 53.1%, respectively, which were similar to results reported in other countries.

SOFA score, multiple organ failure, the provision of organ support such as vasopressor use or mechanical ventilation, and allogeneic hematopoietic stem cell transplantation are known to be predictors of mortality in patients with cancer \[[@b21-acc-2018-00143],[@b22-acc-2018-00143],[@b25-acc-2018-00143],[@b26-acc-2018-00143]\]. We also confirmed that higher SAPS3 value and mechanical ventilation support were associated with poor prognosis in both solid tumor and hematologic malignancy patients. Furthermore, age and premorbid performance status were independent prognostic factors for hospital mortality in patients with solid tumor. Some studies have demonstrated that advanced or recurrent cancer is a variable associated with poor outcomes, but others have suggested that cancer status generally does not affect the short-term outcomes of critically ill cancer patients \[[@b25-acc-2018-00143],[@b27-acc-2018-00143],[@b28-acc-2018-00143]\]. Therefore, intensivists need to be careful when considering cancer status in deciding whether to pursue ICU admission for cancer patients.

Although our study investigated the clinical and treatment characteristics, outcomes, and variables associated with mortality in cancer patients admitted to the 22 medical and surgical ICUs in the Korea, there are several limitations that should be considered. First, our study did not record detailed data about the type, disease status, and treatment of cancer. Although some recent studies have suggested that the disease status of cancer does not adversely affect the short-term outcomes of cancer patients admitted to the ICU, progressive cancer or certain specific conditions, such as those that require mechanical ventilation for respiratory failure due to tumor involvement, are associated with poor prognosis \[[@b25-acc-2018-00143]\]. Therefore, further studies that include additional information on disease status should be conducted to elucidate more accurately the characteristics of and to assess the clinical outcomes in critically ill cancer patients. Also, data about the code status at the time of ICU admission and change(s) in code status during ICU management, which may influence therapeutic decisions and mortality, were not collected. Finally, analyses comparing the cancer patients admitted to the ICU with cancer patients not admitted to the ICU were not performed, and we could not determine whether ICU management is beneficial in cancer patients with acute deterioration.

In conclusion, the proportion of patients with cancer is higher in Korea than in other countries, accounting for about onethird of all patients admitted to the ICU. The most common reason for ICU admission in nonsurgical cancer patients was respiratory problems. Patients with hematologic malignancies had higher severity scores and rates of organ support treatment and mortality than did those with solid tumor. Mechanical ventilation and SAPS3 were independent predictors of hospital mortality in both solid tumor and hematologic malignancy patients.

KEY MESSAGES
============

▪ Cancer patients accounted for one-third of all patients admitted to the studied intensive care units in Korea.

▪ Clinical characteristics were different according to the type of malignancy.

▪ Patients with hematologic malignancies had a worse prognosis than did patients with solid tumor.

No potential conflict of interest relevant to this article was reported.
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###### 

Baseline characteristics of cancer patients admitted to the ICU

  Characteristics                                                           Value
  ------------------------------------------------------------------------- ------------
  Age (yr)                                                                  63 (53-72)
  Male sex                                                                  554 (66.5)
  ECOG performance status[^a^](#tfn1-acc-2018-00143){ref-type="table-fn"}   
   0-1                                                                      349 (44.4)
   2-4                                                                      438 (55.6)
  Comorbidity                                                               
   Hypertension                                                             219 (26.3)
   Diabetes                                                                 153 (18.4)
   Congestive heart failure                                                 30 (3.6)
   Stroke                                                                   35 (4.2)
   Chronic lung disease                                                     14 (1.7)
   Liver cirrhosis                                                          97 (11.6)
   Chronic renal failure                                                    42 (5.0)
  Severity of illness                                                       
   SOFA                                                                     9 (5-12)
   SAPS3                                                                    69 (60-79)
  Location before ICU admission                                             
   Emergency room                                                           377 (45.3)
   General ward                                                             429 (51.5)
   Other ICU                                                                20 (2.4)
   Other                                                                    7 (0.8)
  Treatment history before ICU admission                                    
   Chemotherapy                                                             311 (37.3)
   Radiotherapy                                                             105 (12.6)
   Steroid                                                                  29 (3.5)
  Immune suppression status                                                 79 (9.5)
  CPR before ICU admission                                                  44 (5.3)
  Unplanned ICU admission                                                   620 (74.4)
  Reason for admission                                                      
   Surveillance                                                             228 (27.3)
   Cardiovascular                                                           201 (24.1)
   Respiratory                                                              251 (30.1)
   Neurological                                                             29 (3.5)
   Hepatic                                                                  29 (3.5)
   Digestive                                                                45 (5.4)
   Renal                                                                    9 (1.1)
   Metabolic                                                                12 (1.4)
   Hematological                                                            5 (0.6)
   Other[^b^](#tfn2-acc-2018-00143){ref-type="table-fn"}                    24 (2.9)
  Acute infection at ICU admission                                          427 (51.3)
   Severe sepsis/septic shock                                               312 (37.5)
  Surgical status at ICU admission                                          
   No surgery                                                               736 (88.4)
   Emergent surgery                                                         97 (11.6)

Values are presented as median (interquartile range) or number (%). ICU: intensive care unit; ECOG: Eastern Cooperative Oncology Group; SOFA: Sequential Organ Failure Assessment; SAPS3: Simplified Acute Physiology Score 3; CPR: cardiopulmonary resuscitation.

Data were available for 787 patients;

Includes patients with spinal stenosis, trauma, urinary incontinence, and mood depression disorder.

###### 

Baseline and treatment characteristics according to type of malignancy

  Variable                                                                  Solid tumor (n = 658)   Hematologic malignancies (n=175)   P-value
  ------------------------------------------------------------------------- ----------------------- ---------------------------------- ---------
  Age (yr)                                                                  65 (55-73)              55 (42-65)                         0.005
  Male sex                                                                  452 (70.2)              102 (58.6)                         0.005
  ECOG performance status[^a^](#tfn3-acc-2018-00143){ref-type="table-fn"}                                                              0.928
   0-1                                                                      271 (44.2)              78 (44.6)                          
   2-4                                                                      342 (55.8)              96 (54.9)                          
  Comorbidity (overlapped)                                                                                                             
   Hypertension                                                             191 (29.0)              28 (16.0)                          0.001
   Diabetes                                                                 121 (18.4)              32 (18.3)                          \>0.999
   Congestive heart failure                                                 21 (3.2)                9 (5.1)                            0.251
   Stroke                                                                   28 (4.3)                7 (4.0)                            \>0.999
   Chronic lung disease                                                     11 (1.7)                3 (1.7)                            \>0.999
   Liver cirrhosis                                                          93 (14.1)               4 (2.3)                            \<0.001
   Chronic renal failure                                                    32 (4.9)                10 (5.7)                           0.703
  Severity of illness                                                                                                                  
   SOFA                                                                     8 (4-12)                12 (8-15)                          \<0.001
   SAPS3                                                                    69 (60-79)              71 (63-82)                         \<0.001
  Location before ICU admission                                                                                                        \<0.001
   Emergency room                                                           323 (49.1)              54 (30.9)                          
   General ward                                                             314 (47.7)              115 (65.7)                         
   Other ICU                                                                15 (2.3)                5 (2.9)                            
   Other[^b^](#tfn4-acc-2018-00143){ref-type="table-fn"}                    6 (0.9)                 1 (0.6)                            
  Hospital days before ICU admission                                        0 (0-2)                 0 (0-9)                            0.008
  Treatment history before ICU admission                                                                                               
   Chemotherapy                                                             211 (32.1)              100 (57.1)                         \<0.001
   Radiotherapy                                                             91 (13.8)               14 (8.0)                           0.040
   Steroid                                                                  13 (2.0)                16 (9.1)                           \<0.001
  Immune suppression status                                                 48 (7.3)                31 (17.7)                          \<0.001
  CPR before ICU admission                                                  26 (4.2)                18 (10.5)                          0.001
  Unplanned ICU admission                                                   469 (71.3)              151 (86.3)                         \<0.001
  Reason for ICU admission                                                                                                             
   Surveillance                                                             190 (28.9)              38 (21.7)                          0.070
   Cardiovascular                                                           140 (21.3)              61 (34.9)                          \<0.001
   Digestive                                                                45 (6.8)                0                                  0.001
   Hematological                                                            3 (0.5)                 2 (1.1)                            0.283
   Hepatic failure                                                          29 (4.4)                0                                  0.004
   Metabolic                                                                12 (1.8)                0                                  0.081
   Neurological                                                             20 (3.0)                9 (5.1)                            0.243
   Renal                                                                    7 (1.1)                 2 (1.1)                            1.000
   Respiratory                                                              189 (28.7)              62 (35.4)                          0.095
   Other                                                                    20 (3.0)                1 (0.6)                            0.098
  Acute infection at ICU admission                                          298 (45.3)              129 (73.7)                         \<0.001
   Severe sepsis/septic shock                                               212 (32.2)              100 (57.1)                         \<0.001
  Surgical status at ICU admission                                                                                                     \<0.001
   No surgery                                                               566 (86.0)              170 (97.1)                         
   Emergent surgery                                                         92 (14.0)               5 (2.9)                            
  Initial laboratory variable                                                                                                          
   White blood cell (mm^3^)                                                 9,750 (5,320-15,460)    3,640 (250-9,850)                  \<0.001
   Total bilirubin (mg/dl)                                                  0.9 (0.6-2.1)           1.1 (0.7-2.3)                      0.297
   Creatinine (mg/dl)                                                       1.0 (0.7-1.6)           1.1 (0.7-1.8)                      0.381
   Arterial pH                                                              7.39 (7.30-7.45)        7.40 (7.30-7.46)                   0.159
   Lactic acid (mmol/l)                                                     2.90 (1.70-5.40)        2.65 (1.50-5.23)                   0.468
   C-reactive protein (mg/dl)                                               12.3 (4.3-21.3)         14.5 (6.3-24.3)                    0.082
   Procalcitonin (ng/ml)                                                    3.64 (0.65-22.87)       8.12 (0.19-27.12)                  0.988
   NT-proBNP (pg/ml)                                                        681 (161-3039)          965 (315-6070)                     0.019
  Treatment                                                                                                                            
   Total infused fluids within 24 hr (ml)                                   3,339 (2,275-4,775)     4,039 (3,001-5,246)                \<0.001
   Inotrope/vasopressor within 24 hr                                        293 (44.7)              96 (54.8)                          0.017
    Norepinephrine                                                          251 (38.4)              84 (48.8)                          0.012
    Vasopressin                                                             53 (8.3)                29 (17.2)                          0.001
    Dopamine                                                                64 (10.0)               19 (11.3)                          0.631
    Dobutamine                                                              51 (7.9)                20 (11.8)                          0.108
    Epinephrine                                                             5 (0.8)                 2 (1.2)                            0.643
   Mechanical ventilation                                                   219 (33.3)              82 (46.9)                          0.001
   Continuous renal replacement therapy                                     60 (9.5)                30 (17.6)                          0.004

Values are presented as median (interquartile range) or number (%).

ECOG: Eastern Cooperative Oncology Group; SOFA: Sequential Organ Failure Assessment; SAPS3: Simplified Acute Physiology Score 3; ICU: intensive care unit; CPR: cardiopulmonary resuscitation; NT-proBNP: N-terminal prohormone of brain natriuretic peptide.

Data were available for 787 patients;

Includes patients with spinal stenosis, trauma, urinary incontinence, and mood depression disorder.

###### 

Prognostic factors for hospital mortality

  Variable                                Adjusted OR   95% CI      P-value
  --------------------------------------- ------------- ----------- ---------
  Patient with solid tumor                                          
   Age                                    0.96          0.93-0.99   0.019
   ECOG performance status 2-4            2.63          1.29-5.37   0.008
   Mechanical ventilation                 2.85          1.35-6.04   0.006
   SAPS3                                  1.07          1.04-1.10   \<0.001
  Patient with hematologic malignancies                             
   SAPS3                                  1.05          1.01-1.08   0.006
   Mechanical ventilation                 2.41          1.05-5.55   0.039

OR: odds ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; SAPS3: Simplified Acute Physiology Score 3.

[^1]: The first two authors contributed equally to this study.
